Loading clinical trials...
Loading clinical trials...
A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency
Conditions
Interventions
rAAV1-CB-hAAT
Locations
4
United States
National Jewish Health
Denver, Colorado, United States
University of Massachusetts Medical Center
Worcester, Massachusetts, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Beaumont Hospital
Dublin, Ireland
Start Date
June 1, 2010
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2015
Last Updated
March 28, 2019
NCT00500123
NCT02796937
NCT02900183
NCT06186492
NCT03815396
NCT03767829
Lead Sponsor
Beacon Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions